Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
29 pending office actions • 14 clients • 25 examiners • 14 art units • 0 of 29 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Biospark Intellectual Property Law specializes in Biotechnology & Pharmaceuticals, where it has handled 578 career applications. The firm has a resolved allowance rate of 70.49 percent, which provides a baseline for its success in this complex field. Currently, the firm is managing 18 pending office actions relative to its 578 career applications.
The firm's prosecution process is characterized by an average of 3.44 office actions per allowance. This 3.44 average suggests a thorough and sometimes lengthy negotiation process with the patent office. For practitioners, the 578 career applications and the 70.49 percent resolved allowance rate offer a clear view of the firm's performance. The 18 pending office actions and the 3.44 office actions per allowance metric further illustrate the firm's active workload and its typical path to achieving an allowance. These data points together provide a detailed look at the firm's prosecution history and its effectiveness.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (7%) |
| §103 only | 4 (14%) |
| §102 only | 1 (3%) |
| §112 only | 4 (14%) |
| Double-patenting only | 2 (7%) |
| Double-patenting + other | 5 (17%) |
| Multi-statute (no §101) | 11 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 2 | 68.4% | +30.0% |
| LU, CHENG | 2 | 54.1% | +64.1% |
| DONOGHUE, BRITTNEY ERIN | 2 | 58.8% | +46.5% |
| STONEBRAKER, ALYSSA RAE | 2 | 58.3% | +49.2% |
| MONTANARI, DAVID A | 1 | 64.7% | +49.0% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| SEAMAN, D MARGARET M | 1 | 76.5% | +8.0% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
| GULLEDGE, BRIAN M | 1 | 55.8% | +26.1% |
| RAHMANI, NILOOFAR | 1 | 77.5% | -2.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17613898 | GLUCONATE DEHYDRATASE ENZYMES AND RECOMBINANT CELLS | IANNUZO, NATALIE NMN | 24d overdue |
| 17055511 | BACTERIAL VECTORS FOR GENETIC MANIPULATION OF BACTERIA | LIPPOLIS, ALEXANDRA ROSE | 12d |
| 18700024 | NANOPARTICULATE FORMULATION | ARNOLD, ERNST V | 46d |
| 18615334 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA | RAHMANI, NILOOFAR | — |
| 18417702 | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | LEONARD, ARTHUR S | — |
| 18576878 | MELFLUFEN FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | JAUHARI, SACHI | — |
| 18571367 | CAPSID VARIANTS AND METHODS OF USING THE SAME | CORNELIUS, CLAIRE ADRIENNE | — |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | DONOGHUE, BRITTNEY ERIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | DONOGHUE, BRITTNEY ERIN | 15d overdue |
| 18700024 | NANOPARTICULATE FORMULATION | ARNOLD, ERNST V | 46d |
| 19537081 | CAPSID POLYPEPTIDES AND METHODS OF USE THEREOF | MONTANARI, DAVID A | — |
| 18917773 | COMPOUNDS CONTAINING DEUTERIUM | NOTTINGHAM, KYLE GREGORY | — |
| 18779855 | CAPSID VARIANTS AND METHODS OF USING THE SAME | SALVOZA, M FRANCO G | — |
| 18761730 | CAPSID VARIANTS AND METHODS OF USING THE SAME | SALVOZA, M FRANCO G | — |
| 18670314 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | LU, CHENG | — |
| 18700066 | NANOPARTICULATE FORMULATION | GULLEDGE, BRIAN M | — |
| Art Unit | Apps |
|---|---|
| 1642 | 5 |
| 1644 | 3 |
| 1672 | 2 |
| 1675 | 2 |
| 1632 | 1 |
| 1613 | 1 |
| 1699 | 1 |
| 1691 | 1 |
| 1631 | 1 |
| 1654 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19537081 | CAPSID POLYPEPTIDES AND METHODS OF USE THEREOF | Dyno Therapeutics, Inc. | MONTANARI, DAVID A | 1632 | §112 | Final Rejection | — | Pending | Feb 11, 2026 |
| 18917773 | COMPOUNDS CONTAINING DEUTERIUM | Oncopeptides Innovation AB | NOTTINGHAM, KYLE GREGORY | §112DP | Non-Final OA | — | Pending | Oct 16, 2024 | |
| 18779855 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Dyno Therapeutics, Inc. | SALVOZA, M FRANCO G | DP | Non-Final OA | — | Pending | Jul 22, 2024 | |
| 18400055 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | Oncopeptides AB | SEAMAN, D MARGARET M | §103 | Non-Final OA | — | Pending | Jul 19, 2024 | |
| 18761730 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Dyno Therapeutics, Inc. | SALVOZA, M FRANCO G | DP | Non-Final OA | — | Pending | Jul 02, 2024 | |
| 18670314 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. | LU, CHENG | 1642 | §103DP | Non-Final OA | — | Pending | May 21, 2024 |
| 18700024 | NANOPARTICULATE FORMULATION | Newimmune Ii, LLC | ARNOLD, ERNST V | 1613 | §103§112Other | Final Rejection | 46d | Pending | Apr 10, 2024 |
| 18700066 | NANOPARTICULATE FORMULATION | Newimmune Ii, LLC | GULLEDGE, BRIAN M | 1699 | §103 | Final Rejection | — | Pending | Apr 10, 2024 |
| 18615334 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA | Poolbeg Pharma (Uk) Limited | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18589384 | MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF | Regeneron Pharmaceuticals, Inc. | METCALF, MATTHEW CURRAN | §102§103DP | Non-Final OA | — | Pending | Feb 27, 2024 | |
| 18417702 | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | The Sydney Children's Hospitals Network | LEONARD, ARTHUR S | 1631 | §102§103 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18580810 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. | ALLEN, MARIANNE P | §112 | Non-Final OA | — | Pending | Jan 19, 2024 | |
| 18576878 | MELFLUFEN FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | Oncopeptides Innovation AB | JAUHARI, SACHI | §102§103§112Other | Non-Final OA | — | Pending | Jan 05, 2024 | |
| 18573582 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Dyno Therapeutics, Inc. | CHESTNUT, BARRY A | 1672 | §102 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18571367 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Dyno Therapeutics, Inc. | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§112 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18548772 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. | LU, CHENG | 1642 | §112DP | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112 | Non-Final OA | — | Pending | May 26, 2023 |
| 18133288 | COMPOSITIONS AND METHODS FOR UNIVERSAL TUMOR CELL KILLING | Regeneron Pharmaceuticals, Inc. | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Non-Final OA | — | Pending | Apr 11, 2023 |
| 18247465 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | Abionyx Pharma SA | AUDET, MAURY A | 1654 | §103 | Final Rejection | — | Pending | Mar 31, 2023 |
| 18003279 | IMMUNOTHERAPY | Neogap Therapeutics AB | JUEDES, AMY E | 1644 | §103DP | Final Rejection | — | Pending | Dec 23, 2022 |
| 17928803 | NUCLEIC ACID ENCODING AN ANTI-VEGF ENTITY AND A NEGATIVE COMPLEMENT REGULATOR AND USES THEREOF FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Gyroscope Therapeutics Limited | XIAO, YAN | 1642 | §102§103§112 | Non-Final OA | — | Pending | Nov 30, 2022 |
| 17928798 | METHODS OF PRODUCING RECOMBINANT COMPLEMENT PROTEINS, VECTORS AND THERAPEUTIC USES THEREOF | Novartis Pharmaceuticals UK Limited | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §103§112 | Non-Final OA | — | Pending | Nov 30, 2022 |
| 17909045 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. | GEORGE, DENNIS CHERIAN | 1644 | §101§103§112DP | Non-Final OA | — | Pending | Sep 02, 2022 |
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Non-Final OA | 15d overdue | Pending | Aug 15, 2022 |
| 17735510 | MULTISPECIFIC FGF21 RECEPTOR AGONISTS AND THEIR USES | Regeneron Pharmaceuticals, Inc. | SAOUD, CHRISTINE J | 1600 | §112 | Non-Final OA | — | Pending | May 03, 2022 |
| 17613898 | GLUCONATE DEHYDRATASE ENZYMES AND RECOMBINANT CELLS | BP CORPORATION NORTH AMERICA INC. | IANNUZO, NATALIE NMN | 1653 | §103§112 | Final Rejection | 24d overdue | Pending | Nov 23, 2021 |
| 17612204 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2021 |
| 17417601 | PHAGOCYTISABLE PARTICLE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCER | Neogap Therapeutics AB | JOHANSEN, PETER N. | 1644 | §112 | Non-Final OA | 17d overdue | Pending | Jun 23, 2021 |
| 17055511 | BACTERIAL VECTORS FOR GENETIC MANIPULATION OF BACTERIA | BIOVERSYS AG | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103§112 | Final Rejection | 12d | Pending | Nov 13, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial